Alnylam Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Alnylam Pharmaceuticals CEO'su Yvonne Greenstreet, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı $ 8.90M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11% maaş ve 89% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.039% ine doğrudan sahiptir ve bu hisseler MX$ 253.03M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 9 yıldır.

Anahtar bilgiler

Yvonne Greenstreet

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi	11.0%
CEO görev süresi	2.8yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Yvonne Greenstreet'un ücretlendirmesi Alnylam Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$332m
Jun 30 2024	n/a	n/a	-US$73m
Mar 31 2024	n/a	n/a	-US$332m
Dec 31 2023	US$9m	US$976k	-US$440m
Sep 30 2023	n/a	n/a	-US$510m
Jun 30 2023	n/a	n/a	-US$1b
Mar 31 2023	n/a	n/a	-US$1b
Dec 31 2022	US$5m	US$850k	-US$1b
Sep 30 2022	n/a	n/a	-US$1b
Jun 30 2022	n/a	n/a	-US$981m
Mar 31 2022	n/a	n/a	-US$893m
Dec 31 2021	US$9m	US$619k	-US$853m
Sep 30 2021	n/a	n/a	-US$838m
Jun 30 2021	n/a	n/a	-US$887m
Mar 31 2021	n/a	n/a	-US$876m
Dec 31 2020	US$3m	US$622k	-US$858m
Sep 30 2020	n/a	n/a	-US$891m
Jun 30 2020	n/a	n/a	-US$846m
Mar 31 2020	n/a	n/a	-US$886m
Dec 31 2019	US$3m	US$571k	-US$886m
Sep 30 2019	n/a	n/a	-US$821m
Jun 30 2019	n/a	n/a	-US$858m
Mar 31 2019	n/a	n/a	-US$802m
Dec 31 2018	US$3m	US$540k	-US$761m
Sep 30 2018	n/a	n/a	-US$692m
Jun 30 2018	n/a	n/a	-US$570m
Mar 31 2018	n/a	n/a	-US$525m
Dec 31 2017	US$985k	US$504k	-US$491m

Tazminat ve Piyasa: Yvonne 'nin toplam tazminatı ($USD 8.90M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.71M ).

Tazminat ve Kazançlar: Yvonne şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Yvonne Greenstreet (61 yo)

2.8yrs

Görev süresi

US$8,895,670

Tazminat

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yvonne Greenstreet	CEO & Director	2.8yrs	US$8.90m	0.039% MX$ 253.0m
Jeffrey Poulton	CFO & Executive VP	5.3yrs	US$3.22m	0.016% MX$ 107.1m
Akshay Vaishnaw	Chief Innovation Officer & Member of the Scientific Advisory Board	1.1yrs	US$3.32m	0.018% MX$ 117.7m
Pushkal Garg	Chief Medical Officer	10.1yrs	US$3.23m	0.0090% MX$ 58.8m
Tolga Tanguler	Executive VP & Chief Commercial Officer	3.8yrs	US$2.87m	0.0054% MX$ 34.9m
Timothy Maines	Chief Technical Operations & Quality Officer	1.8yrs	Veri yok	Veri yok
Kevin Fitzgerald	Senior VP	5.5yrs	Veri yok	0.010% MX$ 67.8m
Piyush Sharma	Chief Ethics & Compliance Officer	2.2yrs	Veri yok	Veri yok
Robert Hesslein	Chief Legal Officer & Corporate Secretary	less than a year	Veri yok	Veri yok
Christine Lindenboom	Chief Corporate Communications Officer	no data	Veri yok	Veri yok
Evan Lippman	Chief Corporate Development & Strategy Officer	2.2yrs	Veri yok	Veri yok
Kelley Boucher	Chief Human Resource Officer	5.5yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: ALNY * 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yvonne Greenstreet	CEO & Director	3.1yrs	US$8.90m	0.039% MX$ 253.0m
Akshay Vaishnaw	Chief Innovation Officer & Member of the Scientific Advisory Board	no data	US$3.32m	0.018% MX$ 117.7m
Muthiah Manoharan	Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board	9.1yrs	Veri yok	Veri yok
Peter Kellogg	Independent Director	1.7yrs	US$658.72k	0% MX$ 0
Paul Schimmel	Member of the Scientific Advisory Board	no data	US$516.04k	Veri yok
David E. Pyott	Independent Director	8.9yrs	US$477.21k	0.022% MX$ 141.6m
Phillip Sharp	Co-Founder	22.4yrs	US$502.21k	0.21% MX$ 1.3b
Amy W. Schulman	Independent Chair of the Board & Lead Independent Director	10.3yrs	US$531.36k	0.0065% MX$ 42.6m
Markus Stoffel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
David Bartel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Dennis Ausiello	Member of the Scientific Advisory Board & Independent Director	12.6yrs	US$477.21k	0.0028% MX$ 18.4m
Colleen Reitan	Independent Director	6.4yrs	US$489.15k	0% MX$ 0

9.0yrs

Ortalama Görev Süresi

69.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALNY * 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9 yıldır).

Alnylam Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO & Director recently sold Mex$35m worth of stock

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

CEO & Director recently sold Mex$18m worth of stock

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

President recently sold Mex$13m worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023)

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$2.21 loss in 2Q 2023)

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director recently sold Mex$35m worth of stock

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

CEO & Director recently sold Mex$18m worth of stock

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

President recently sold Mex$13m worth of stock

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

CEO & Director recently sold Mex$27m worth of stock

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD

Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$1.15 loss per share (vs US$1.61 loss in 2Q 2021)

Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022

No longer forecast to breakeven

Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of Iga Nephropathy

Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering Rna to the Central Nervous System and Other Extrahepatic Tissues

Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis of Exploratory Cardiac Endpoints in the HELIOS-A Phase 3 Study of Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces That Health Canada Has Issued A Notice of Compliance (Noc) Authorizing Oxlumo™ (Lumasiran) Injection for Subcutaneous Use for the Treatment

First quarter 2022 earnings released: US$2.00 loss per share (vs US$1.71 loss in 1Q 2021)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Alnylam Pharmaceuticals, Inc. Announces Retirement of Steven Paul from Board of Directors

Alnylam Pharmaceuticals, Inc. Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat